Skip to content

CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please ensure that you fully understand the risks involved.

UK stock preview: AstraZeneca, ASOS, Anglo American

Here are three LSE mainboard stocks to watch this week.

astrazeneca asos anglo american share price latest live target rating Source: Bloomberg
  • AstraZeneca share price rose slightly on Monday morning (11 October), after it reported positive results from a Covid-19 treatment trial
  • ASOS share price plunges nearly 15% after it announced that Nick Beighton will step down as CEO
  • Anglo American share price rallies 4% after it bought back 125,000 ordinary shares
  • Keen to take advantage of rising and falling share prices? Open an account with us to long or short these stocks now.

AstraZeneca (LON: AZN)

Biotechnology company AstraZeneca reported positive high-level results from its TACKLE Phase III Covid-19 treatment trial.

The trial showed that AstraZeneca's AZD7442, a long-acting antibody (LAAB) combination, achieved a statistically significant reduction in severe Covid-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic Covid-19.

A total of 90% of participants enrolled were from populations at high risk of progression to severe Covid-19, including those with co-morbidities.

The trial was said to have ‘met the primary endpoint, with a dose of 600mg of AZD7442 given by intramuscular (IM) injection reducing the risk of developing severe COVID-19 or death (from any cause) by 50% compared to placebo in outpatients who had been symptomatic for seven days or less’.

In a prespecified analysis of participants who received treatment within five days of symptom onset, AZD7442 reduced the risk of developing severe Covid-19 or death (from any cause) by 67% compared to placebo.

ASOS (LON: ASC)

ASOS has announced a series of changes to its Board, as part of ‘the next phase of its global growth strategy’.

Nick Beighton will step down as Chief Executive Officer after 12 years with the business, including six as CEO. A search is commencing for a successor. He will remain available to the Board until the end of 2021 to ensure a smooth handover.

Mat Dunn, currently Chief Financial Officer, will take on the additional role of Chief Operating Officer and lead the business on a day-to-day basis, while Katy Mecklenburgh, currently Director of Group Finance, will become Interim Chief Financial Officer. These changes will take place with immediate effect.

Separately, the online fashion marketplace also issued its annual results for the year ending 31 August 2021, in which UK sales grew 36% year-on-year on the back of higher customer numbers.

The business has also set out plans deliver annual revenues of £7bn and an EBIT margin of at least 4%, within three to four years.

Anglo American (LON: AAL)

Anglo American announced that it has purchased 125,000 of its US$0.54945 ordinary shares from Goldman Sachs International, as part of its buyback programme announced on 29 July 2021.

On 08 October 2021, the mining company paid a volume weighted average price £26.9901 per share.

AAL will cancel the purchased shares.

Keen to trade AstraZeneca, ASOS and Anglo American shares?

Go short and long with CFDs on these three UK stocks and 16,000+ shares with our award winning platform.* Learn more about trading shares with us, or open an account to get started today.

* Based on the Investment Trends 2018 Singapore CFD & FX Report based on a survey of over 4,500 traders and investors. Awarded the Best Online Trading Platform by Influential Brands in 2020. Awarded the best retail FX provider for Asia by FX Markets in 2020

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.

Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Tuesday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.